Prion Diseases — Creutzfeldt-Jakob

• Prion protein misfolding and templating: The normal cellular prion protein (PrP^C) is a glycoprotein anchored to cell membranes and expressed ubiquitously, particularly in neurons. In CJD, an abnormally folded isoform (PrP^Sc) acts as a template that recruits normal PrP^C molecules and converts them into the pathogenic conformation through a process of self-propagating protein misfolding. This chain reaction occurs through direct protein-protein interaction, where the β-sheet-rich PrP^Sc provides a template that induces PrP^C to refold from its native α-helical structure into a β-pleated sheet configuration. This templating mechanism is unique among neurodegenerative diseases and explains both the infectivity of CJD and its progressive nature—once initiated, the conversion cascade becomes self-sustaining. The accumulation of PrP^Sc can occur intracellularly, extracellularly, or in both compartments depending on the CJD subtype, creating distinct pathological patterns.

• Spongiform degeneration and neuronal loss: The accumulation of PrP^Sc triggers a stereotyped pathological response characterized by spongiform degeneration—the formation of vacuoles within the neuropil creating a "Swiss cheese" appearance on histology. This occurs primarily in the cerebral cortex, basal ganglia, and thalamus, though the pattern varies by CJD subtype. The mechanism underlying spongiform change involves both direct toxicity from PrP^Sc aggregates and secondary neuroinflammatory responses. PrP^Sc aggregates damage neuronal membranes directly through oxidative stress and disruption of cellular calcium homeostasis. Additionally, neuronal loss occurs through apoptotic and autophagic pathways triggered by proteotoxic stress. Astrogliosis (activation and proliferation of astrocytes) and microglial activation occur in response to neuronal injury, further contributing to neurodegeneration through release of pro-inflammatory cytokines and reactive oxygen species. The specific pattern of regional involvement determines the clinical phenotype—cortical predominance produces rapidly progressive dementia, cerebellar involvement causes ataxia, and thalamic involvement can produce insomnia and hyperreflexia (variant form).

• Synaptic dysfunction and network disruption: PrP^Sc accumulation leads to disruption of synaptic architecture and neurotransmitter dysfunction before overt neuronal death occurs. Normal PrP^C appears to play a role in synaptic plasticity and stability; its pathogenic conversion disrupts these functions. Studies indicate that PrP^Sc interferes with cellular signaling pathways including N-methyl-D-aspartate (NMDA) receptor function, resulting in excitotoxicity from excessive glutamate signaling. Additionally, PrP^Sc impairs mitochondrial function by disrupting calcium buffering capacity, leading to increased oxidative stress and energy depletion. The early neuronal loss of synaptic contacts (synapse loss exceeds neuronal loss in early disease) explains why cognitive symptoms and ataxia precede substantial neuronal death, suggesting that toxic prion-protein interactions have functional consequences before morphologic neuronal death is evident.

• Genetic and molecular determinants of disease phenotype: The prion protein gene (PRNP) contains a polymorphism at codon 129 (encoding either methionine or valine), which dramatically influences disease susceptibility, incubation period, and clinical phenotype. Homozygosity at codon 129 (MM or VV genotype) is associated with higher disease susceptibility and shorter incubation periods compared to heterozygosity (MV). Additionally, different PrP^Sc conformational isoforms ("strains") exhibit distinct propagation rates and neuropathological patterns, producing distinct clinical syndromes even within sporadic CJD. The MM genotype at codon 129 combined with Type 1 PrP^Sc (distinguished by protease-resistant PrP molecular weight) produces the most common sporadic CJD form with rapidly progressive dementia. Type 2 PrP^Sc and heterozygous genotypes tend to produce variant phenotypes with longer disease duration and different symptom profiles. In familial CJD, specific mutations in PRNP (such as E200K, V210I, or M232R) determine clinical presentation and penetrance, with some mutations showing reduced penetrance even in homozygous carriers.

• Breakdown of the blood-brain barrier and immune responses: While prion diseases were historically considered "non-inflammatory," accumulating evidence indicates that neuroinflammation contributes significantly to CJD pathogenesis. PrP^Sc-induced activation of resident microglia and recruitment of peripheral immune cells triggers production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and chemokines. This neuroinflammatory response, while potentially part of an innate defense mechanism, paradoxically accelerates neurodegeneration by amplifying oxidative stress and promoting neuronal apoptosis. In sporadic CJD, the blood-brain barrier (BBB) remains largely intact, limiting the peripheral immune response, whereas in iatrogenic and variant forms, BBB disruption may allow more robust immune activation. The presence of cerebrospinal fluid (CSF) biomarkers of neuroinflammation (phosphorylated tau, neurofilament light chain) indicates that neuroinflammatory cascades parallel disease progression.

• Sporadic CJD (sCJD) — the predominant form: Accounts for approximately 85% of all CJD cases with an incidence of 0.5–2 per million per year. The etiology remains incompletely understood; sporadic cases arise apparently de novo without identifiable exogenous source or inherited mutation. Leading hypotheses include spontaneous somatic mutations in PRNP in certain cell lineages, stochastic misfolding of PrP^C with age, and possible exposure to infectious agent from environmental sources (food, occupational). Age at onset typically ranges from 60–70 years with rapid progression over 6–12 months. The codon 129 polymorphism and PrP^Sc type (Type 1 vs Type 2) create distinct sCJD phenotypes (sCJD-MM1, sCJD-MV1, sCJD-VV1, sCJD-MV2, sCJD-VV2 etc.), each with characteristic clinical features and progression rates. sCJD demonstrates no clear environmental or lifestyle risk factors, though some case-control studies have suggested possible associations with surgical procedures, blood transfusion, or occupational exposures (veterinary work, butchering); however, these associations remain unproven and controversial.

• Familial/Inherited CJD (fCJD) — germline PRNP mutations: Account for 10–15% of CJD cases and result from autosomal dominant pathogenic variants in the PRNP gene. The most common mutation is E200K, found predominantly in Libyan Jewish, Tunisian, and other Mediterranean populations, causing earlier disease onset (mean age 55 years) and variable clinical presentation. Other mutations include V210I (associated with Icelandic and Swedish families), M232R, P102L, and others. Penetrance varies by mutation (near complete for E200K, reduced for some mutations), and heterozygous carriers show variable expressivity even within families. The mechanism involves a gain-of-function where the mutant PrP^C is inherently more prone to misfolding, reducing the threshold for spontaneous conversion. Genetic testing of asymptomatic family members raises ethical issues regarding disclosure of risk without the ability to prevent disease. Family history should prompt detailed questioning about dementia, ataxia, insomnia, or death from neurodegenerative disease in relatives; even negative family history does not exclude fCJD due to possible incomplete penetrance, de novo mutations, or misdiagnosis in deceased relatives.

• Iatrogenic CJD (iCJD) — exogenous transmission: Accounts for 1–2% of cases and results from accidental exposure to infectious prions through medical procedures. Classic exposures include: (1) contaminated neurosurgical instruments — prions are remarkably resistant to standard sterilization (including autoclaving at 134°C), and at least 10 cases resulted from inadequately sterilized electroencephalography (EEG) electrodes or surgical instruments; (2) dura mater grafts — more than 100 cases of iCJD occurred from implantation of dura mater allografts contaminated with prions, particularly in Japan where cadaveric dura was used without prion-inactivating procedures (current grafts are prion-inactivated or synthetic); (3) corneal transplants — rare cases documented; (4) growth hormone preparations — before 1985, human-derived growth hormone (hGH) extracted from pituitary glands caused over 200 cases of iCJD, particularly in France and the United Kingdom (now replaced by recombinant hormone); and (5) gonadotropin preparations — extracted from human urine, caused rare cases. Incubation periods for iCJD range from 4 to >30 years depending on inoculum dose and route, with longer incubations seen in dura mater recipients and shorter incubations in cases of direct intracerebral inoculation (e.g., electrode-related cases). Iatrogenic CJD often presents with atypical phenotypes, particularly ataxia-predominant presentations, reflecting the direct neural seeding.

• Variant CJD (vCJD) — bovine spongiform encephalopathy transmission: The only documented example of cross-species prion transmission to humans, vCJD resulted from consumption of beef contaminated with bovine spongiform encephalopathy (BSE) prions, predominantly in the United Kingdom from the 1980s–1990s. Over 230 cases of vCJD have been documented globally, with the vast majority from the UK. vCJD characteristically affects younger individuals (median age 28 years at onset), contrasting sharply with sCJD's elderly presentation. The clinical features are distinctive: prominent psychiatric and sensory symptoms dominate early stages (depression, anxiety, dysphoria, paresthesias), followed by ataxia and cognitive decline, with dementia emerging later in the course. neuropathological examination shows PrP^Sc deposition primarily in lymphoid tissues and tonsil before CNS involvement, and MRI shows a characteristic "pulvinar sign" (T2/FLAIR hyperintensity in the pulvinar nucleus of the thalamus). Disease progression is slower than sCJD (average 13 months vs 6 months), and the codon 129 genotype is predominantly MM in documented cases, raising concern that heterozygotes and VV individuals may represent a "hidden" epidemic with longer incubation periods. The BSE outbreak was linked to feeding of ruminant-derived protein supplements to cattle (a practice since banned), demonstrating the zoonotic potential of prion diseases.

• Sports-related and occupational exposures — uncertain causation: Occasional case reports have linked CJD to participation in contact sports (football, rugby) or occupational exposures (butchering, hunting, veterinary medicine) through proposed traumatic inoculation of contaminated tissue or environmental exposure. However, epidemiologic evidence remains weak, and confounding by age and other factors has not been adequately controlled. Current evidence does not support restriction of these activities as a precaution against CJD, though universal precautions for handling potentially infectious tissue remain prudent.

• Rapidly progressive cognitive decline — the cardinal feature: The hallmark presentation is unexpectedly rapid cognitive deterioration that patients and families recognize as dramatic change over weeks to months rather than gradual decline over years. Memory loss (both anterograde and retrograde) typically emerges first, followed by progressive impairment of executive function, visuospatial abilities, and language. In contrast to other dementias (Alzheimer disease, frontotemporal dementia) that evolve over years, sCJD progression is relentless—patients often become severely demented and bedbound within 6 months of symptom onset. The rate of cognitive decline can be quantified using formal testing (mini-cognitive assessment score deteriorating by ≥2 points per month), which distinguishes sCJD from other rapidly progressive dementias. Early cognitive involvement reflects the cortical predominance of pathology in most sCJD subtypes; the default mode network and regions critical for episodic memory (medial temporal lobe) are affected early in some variants. Fluctuations in cognition may occur, distinguishing CJD from some other progressive dementias; some patients report good days and bad days early in disease course.

• Myoclonus — jerking movements indicating cortical hyperexcitability: Myoclonus occurs in approximately 90% of sCJD cases, typically manifesting as irregular, sudden, brief jerking of limbs that may be stimulus-sensitive (triggered by noise, tactile stimulation, or movement). The myoclonus reflects cortical hyperexcitability from the loss of inhibitory interneurons and spongiform disruption of cortical circuitry. Early myoclonus may be subtle and episodic, then become more frequent and generalized as disease progresses. The electromyographic (EMG) pattern of myoclonus in CJD characteristically shows brief bursts (50–200 milliseconds) of motor unit action potentials, distinct from asterixis (flapping tremor) or seizures. Myoclonus severity correlates with cognitive decline rate and overall disease severity. In some CJD variants (particularly VV2 sCJD), myoclonus is minimal or absent, whereas in MM1 sCJD it is nearly universal. Myoclonus can be provoked in patients during examination by sudden auditory stimuli or pinching the skin, aiding diagnosis.

• Cerebellar ataxia and gait disturbance: Ataxia manifests as incoordination of limb movements, truncal instability, and gait disorder reflecting cerebellar pathology and/or cerebellar-cortical disconnection. Patients exhibit positive Romberg test (inability to stand with eyes closed), dysmetria (inability to accurately direct limb movements to targets), intention tremor, and nystagmus (particularly downbeating nystagmus). Gait ataxia is often the most disabling feature, with rapid progression to inability to ambulate independently within weeks to months. The severity and tempo of ataxia varies by CJD subtype: cerebellar predominance characterizes ataxic variants of sCJD (particularly VV2 and MV2 sCJD subtypes), while ataxia is less prominent in other MM1 subtypes that feature primarily cognitive and motor symptoms. Early recognition of prominent ataxia should prompt consideration of variant CJD (vCJD), which frequently presents with prominent ataxia, or iatrogenic CJD from neural inoculation. In iatrogenic cases seeded directly into the cerebellum, ataxia may dominate the clinical picture while cognitive decline progresses more slowly than in typical sCJD.

• Visual disturbances and cortical blindness: Approximately 60% of CJD patients develop visual symptoms, ranging from blurred vision to progressive cortical blindness. Manifestations include visual field defects (often homonymous hemianopia reflecting parietal or occipital cortical involvement), photopsia (flashing lights or visual snow), and progressive visual decline despite intact peripheral vision and pupillary responses. Some patients describe "visual snow" — a constant background of visual static resembling television static. Blindness occurs as a late feature in many cases, related to extensive p

• Serum/metabolic screen: B12, TSH, HIV, RPR/treponemal testing, ammonia, heavy metals (bismuth, lithium toxicity mimics myoclonic encephalopathy).
• Autoimmune/paraneoplastic panel: serum and CSF anti-NMDAR, LGI1, CASPR2, GAD65, and anti-thyroid antibodies (Hashimoto encephalopathy) — these are steroid- or immunotherapy-responsive and are the highest-yield mimics on exams.
• Routine CSF: cell count, protein, glucose, cytology. In CJD the CSF is characteristically bland; pleocytosis argues strongly against prion disease and for infection, autoimmunity, or lymphoma.

Step 2 — imaging (highest-yield initial test)

• Brain MRI with DWI/ADC: the single most useful imaging study. Look for cortical ribboning (gyriform DWI hyperintensity) plus caudate and putamen hyperintensity, with restricted diffusion on ADC. In variant CJD, the pulvinar sign (bilateral posterior thalamic hyperintensity) predominates. DWI abnormality precedes atrophy and is far more sensitive than FLAIR alone.

Step 3 — CSF prion biomarkers

• RT-QuIC (real-time quaking-induced conversion): the confirmatory in-vivo test, exploiting PrP^Sc's own templating activity to seed amplification in vitro. Sensitivity and specificity are both high (specificity near-absolute), and its incorporation into the CDC surveillance case definition for sporadic CJD made it the assay of choice.
• 14-3-3 protein, total tau, neuron-specific enolase: nonspecific markers of rapid neuronal lysis. Elevated in stroke, encephalitis, and seizures — supportive only, never diagnostic.

Step 4 — ancillary and definitive testing

• EEG: periodic sharp wave complexes at roughly 1 Hz, classic for MM1 sporadic CJD but insensitive and typically absent in variant CJD.
• ***PRNP* sequencing**: identifies familial disease (E200K, others) and codon 129 genotype; requires genetic counseling.
• Definite diagnosis requires neuropathology: brain biopsy or, far more commonly, autopsy showing spongiform change with immunohistochemistry or Western blot for protease-resistant PrP^Sc. In the US, cases are referred to the National Prion Disease Pathology Surveillance Center.

Immediate priorities at diagnosis

• Goals-of-care discussion and early palliative/hospice referral: median survival in sporadic disease is measured in months. Advance directives, surrogate decision-making, and decisions about feeding tubes and hospitalization should be addressed while the patient can still participate.
• Aspiration and safety assessment: formal swallow evaluation and fall precautions, since dysphagia and ataxia appear early.

Symptom-directed pharmacotherapy

• Myoclonus — benzodiazepines: clonazepam is first-line, enhancing GABA-A–mediated inhibition to dampen cortical hyperexcitability. Sedation limits dosing.
• Second-line antimyoclonic agents: levetiracetam or valproate; these are the usual escalation when clonazepam is inadequate or intolerable.
• Depression/anxiety — SSRIs: sertraline or similar, particularly relevant in variant CJD where psychiatric symptoms dominate early.
• Agitation/psychosis — atypical antipsychotics, used sparingly and at the lowest effective dose; the FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis applies.
• Spasticity and pain: standard palliative measures, including opioids in the terminal phase.

Infection control (the exam-relevant "procedure")

• Standard precautions suffice for routine care — CJD is not transmitted by casual contact, respiratory droplets, or shared living space. No isolation room is required.
• Neurosurgical and ophthalmic instruments require prion-specific decontamination per WHO/CDC recommendations: disposable instruments when possible, otherwise 1N sodium hydroxide or sodium hypochlorite followed by prolonged extended-cycle autoclaving. Routine autoclaving alone is inadequate.
• Autopsy is encouraged (definitive diagnosis, surveillance, family counseling) with prion-appropriate handling; formic acid treatment of fixed tissue reduces infectivity.

Neurologic progression

• Akinetic mutism: the terminal state of nearly all patients, reflecting widespread cortical and thalamocortical network destruction. The patient is awake but unresponsive, immobile, and non-verbal — a prognostic marker of imminent death, not a reversible catatonia.
• Status myoclonus and seizures: escalating cortical hyperexcitability may generalize. Convulsive status epilepticus is a medical emergency requiring benzodiazepine plus antiseizure loading, though it does not change the disease trajectory.
• Cortical blindness: progressive occipital involvement produces vision loss with intact pupillary reflexes — a diagnostic clue and a major source of falls.

Immobility and bulbar failure — the actual causes of death

• Aspiration pneumonia: bulbar dysfunction and impaired cough are the leading terminal event. Signals include new fever, hypoxemia, and a dependent-lobe infiltrate. Emergency — treat or transition to comfort care per goals of care.
• Malnutrition and dehydration: from dysphagia and inability to self-feed; weight loss is often dramatic. Feeding-tube placement is a goals-of-care decision, not a default.
• Venous thromboembolism: immobility-driven stasis; sudden dyspnea, tachycardia, or hypoxemia signals pulmonary embolism — an emergency.
• Pressure injuries, contractures, urinary tract infection: consequences of bed-bound status and incontinence.

Complications of therapy

• Benzodiazepine oversedation: clonazepam used for myoclonus causes respiratory depression and worsens aspiration risk; a sudden drop in arousal in a patient on escalating doses should prompt dose review before assuming disease progression.
• Antipsychotic-related harm: extrapyramidal worsening, QT prolongation, and excess mortality in dementia (FDA boxed warning).
• Valproate: hyperammonemic encephalopathy and hepatotoxicity can masquerade as disease progression.

Iatrogenic transmission — the public-health complication

• Contaminated neurosurgical, ophthalmic, or EEG-depth-electrode instruments can transmit prions because standard sterilization fails. Any invasive CNS procedure in a suspected case mandates CDC/WHO prion decontamination protocols or single-use equipment. A missed diagnosis before neurosurgery is the scenario examiners use.

• The triad that defines the stem: rapidly progressive dementia over weeks to months + myoclonus (often startle-induced) + ataxia in a patient around age 60–70. Any dementia progressing this fast is CJD until proven otherwise.
• Single best next step in a suspected case: brain MRI with DWI, looking for cortical ribboning and caudate/putamen restricted diffusion — before EEG, before CSF. Then send CSF RT-QuIC, the confirmatory antemortem test.
• 14-3-3 is the classic distractor: it is a marker of rapid neuronal death, not of prions, and rises in stroke, encephalitis, and seizures. Choosing 14-3-3 over RT-QuIC as the "most specific test" is the standard trap.
• EEG buzzword: periodic sharp wave complexes at about 1 Hz. Present in classic sporadic (MM1) disease, typically absent in variant CJD — don't expect it in a young patient with psychiatric onset.
• Sporadic vs variant: elderly + dementia-first + PSWC on EEG + cortical ribboning = sporadic. Young adult (median ~28) + psychiatric/sensory onset + pulvinar sign on MRI + UK beef exposure = variant CJD, with detectable PrP^Sc in tonsillar lymphoid tissue.
• The association examiners love: codon 129 PRNP polymorphism — homozygosity (MM or VV) increases susceptibility and shortens incubation; MM predominates in variant CJD.
• Before calling it CJD, exclude the treatable mimic: autoimmune/paraneoplastic encephalitis (anti-NMDAR, LGI1), Hashimoto encephalopathy, B12 deficiency, neurosyphilis, HIV. CSF pleocytosis points away from prion disease.
• Infection control: standard precautions for routine care — no isolation, no droplet precautions. But prions survive routine autoclaving; neurosurgical instruments require WHO/CDC prion-specific decontamination or disposal. Patients are permanently deferred from blood and organ donation (FDA).
• Definite diagnosis requires tissue (biopsy or autopsy) showing spongiform change and protease-resistant PrP^Sc; there is no disease-modifying therapy, and management is palliative with clonazepam for myoclonus.